August 11, 2025
After 1 positive of 10 negative closes <since 7/28> and 6 negative closes <since 8/1>
Today’s main takeaway … traversing the volatility tripwire! While, inflation readings this week will prove a key hurdle for a broad market index near record highs. The consumer price index, which is set to be released Tuesday, and the producer price index, due out Thursday, will be critical in shaping the outlook for the direction of interest rates, especially for the Fed’s September meeting. Hotter inflation could hinder the market’s advance. Inflation data comes ahead of the Fed’s Jackson Hole meeting in Wyoming on Aug. 21-23, which will likely set the tone for the September meeting.
Earnings: 8/11, Monday = Agenus (AGEN) and Compass Therapeutics (CMPX)
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!
Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!
August 10, 2025
On October 31, 2013, Harvard Bioscience (HBIO), spun-off contributing its regenerative medicine business assets, plus $15 M of cash, into Harvard Apparatus Regenerative Technology, then it became Biostage (OTCQB: BSTG) and now back to its present, Harvard Apparatus Regenerative Technology (OTCQB: HRGN).
Now, they’re all but BROKE filing for yet another PPM to come! What valuation model would even/ever justify this PPM pricing?
Will an “Exempt Offering of Securities” emanate from its board management and “quiet” < Lui Dong Hai, chairman of Dixintong Technology Group (D. Phone, the largest smartphone retailer in China) the husband of Mrs. bin (Zhao)> majority members are from or reside in Beijing, PRC.
Challenging facts state the obvious – a Ponzi Scheme, a Madoff look-a-like or just a PRC, Communist China “listening/monitoring post” in Holliston, Mass?
U.S. investors BEWARE, forewarned is forearmed?
August 11, 2025
The present and future value of RegMed Investors (RMi) analysis sheds light on the cell and gene therapy sector’s “current” acrobatics
Earnings: Agenus (AGEN) and Compass Therapeutics (CMPX) <see The Bottom Line>
The thing about trading stocks is everyone has an opinion. There is a distinct difference between investing with indication intelligence and/or guidance to understand potential risks and reward.
Never leave an investor uninformed!
August 10, 2025
On October 31, 2013, Harvard Bioscience (HBIO), spun-off contributing its regenerative medicine business assets, plus $15 M of cash, into Harvard Apparatus Regenerative Technology, then it became Biostage (OTCQB: BSTG) and now back to its present, Harvard Apparatus Regenerative Technology (OTCQB: HRGN). Twelve (12) years, Nine (9) private placements (PPM), 3 corporate re-names, 4 CEOs, 2 presidents, 5 CFOs with still NO clinical response <patient recruitment issues> since the November 1, 2013 spin-off completed. Now, they’re all but BROKE filing for yet another PPM to come! What valuation model would even/ever justify this PPM pricing? WHO is their major shareholder – DST Capital, OTCQB: HRGN’s in-house fund run by its president Hong Yu, funded by Mrs. bin (Zhao) of Weston, Mass. Will an “Exempt Offering of Securities” emanate from its board management and “quiet” < Lui Dong Hai, chairman of Dixintong Technology Group (D. Phone, the largest smartphone retailer in China) the husband of Mrs. bin (Zhao)> majority members are from or reside in Beijing, PRC. Are they up to their old tricks, they just don’t stop? Challenging facts state the obvious – a Ponzi Scheme, a Madoff look-a-like or just a PRC, Communist China “listening/monitoring post” in Holliston, Mass? U.S. investors BEWARE, forewarned is forearmed?
August 1, 2025
PRME closed Friday at $4.04 ... And the full exercise of the 5.7 K underwriters’ option at $3.30 per share. The gross proceeds before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 M. TD Cowen and BMO Capital Markets are acting as joint book-running managers for the proposed offering.
June 17, 2025
Gene therapy companies are riding a new waave ... Verve Therapeutics (VERV +$4.79 or +76.31 to $11.06) rallied after the gene editing company agreed to be acquired by Eli Lilly (LLY -$9.13 or -1.15% to $798.28) or $10.50 per share, a premium of 67.5% on the company’s last close. The deal, which is worth up to $1.3 billion, is expected to close in Q3/25. The 2 companies were already partnered on a handful of 1-time treatments for cardiovascular diseases. VERV's leading program would use gene editing to permanently turn off the PCSK9 gene. The gene makes a protein that, when elevated, leads to high cholesterol. LLY also agreed to pay an additional $3 per share in a contingent value right. Lilly will pay the CVR when the first patient receives Verve's leading drug in a U.S. P3 study for atherosclerotic cardiovascular disease.
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
